Literature DB >> 12480286

Buccal delivery of thiocolchicoside: in vitro and in vivo permeation studies.

M Artusi1, P Santi, P Colombo, H E Junginger.   

Abstract

Thiocolchicoside, a muscle-relaxant agent, is administered by the oral, intra-muscular and topical route. After oral administration the extent of bioavailability compared with intra-muscular administration is low, due to a first pass effect. In this paper, the delivery of thiocolchicoside through oral mucosa is studied to improve the bioavailability. Thiocolchicoside in vitro permeation through porcine oral mucosa and in vivo buccal transport in humans were investigated. Two dosage forms, a bioadhesive disc and a fast dissolving disc for buccal and sublingual administration of thiocolchicoside, respectively, were designed. The in vitro permeation of thiocolchicoside through porcine buccal mucosa from these dosage forms was evaluated and compared with in vivo absorption. Results from in vitro studies demonstrated that thiocolchicoside is quite permeable across porcine buccal mucosa and that permeation enhancers, such as sodium taurocholate and sodium taurodeoxycholate, were not able to increase its flux. The in vivo thiocolchicoside absorption experiments, in which the drug loss from oral cavity was measured, indicated that both formulations could be useful for therapeutic application. The fast dissolving (sublingual) form resulted in a quick uptake of 0.5 mg of thiocolchicoside within 15 min whereas with the adhesive buccal form the same dose can be absorbed over an extended period of time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12480286     DOI: 10.1016/s0378-5173(02)00545-8

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  In silico prediction of drug permeability across buccal mucosa.

Authors:  Amit Kokate; Xiaoling Li; Paul J Williams; Parminder Singh; Bhaskara R Jasti
Journal:  Pharm Res       Date:  2009-01-30       Impact factor: 4.200

2.  In vitro evaluation of mucoadhesive films for gingival administration of lidocaine.

Authors:  Cristina Padula; Laura Pozzetti; Valeria Traversone; Sara Nicoli; Patrizia Santi
Journal:  AAPS PharmSciTech       Date:  2013-12       Impact factor: 3.246

3.  Effect of experimental temperature on the permeation of model diffusants across porcine buccal mucosa.

Authors:  Upendra Dilip Kulkarni; Ravichandran Mahalingam; Xiaoling Li; Indiran Pather; Bhaskara Jasti
Journal:  AAPS PharmSciTech       Date:  2011-05-04       Impact factor: 3.246

4.  Digital Image Disintegration Analysis: a Novel Quality Control Method for Fast Disintegrating Tablets.

Authors:  Osamah Malallah; Zara Rashid; Chee Lok Li; Abdulmalik Alqurshi; Mohamed A Alhanan; Ben Forbes; Paul G Royall
Journal:  AAPS PharmSciTech       Date:  2021-08-16       Impact factor: 3.246

5.  Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy.

Authors:  Fiona McInnes; Nicola Clear; Gerry James; Howard N E Stevens; Unai Vivanco; Michael Humphrey
Journal:  Pharm Res       Date:  2007-09-01       Impact factor: 4.200

6.  Penetration and distribution of thiocolchicoside through human skin: comparison between a commercial foam (Miotens) and a drug solution.

Authors:  Carola Aguzzi; Silvia Rossi; Michela Bagnasco; Luigi Lanata; Giuseppina Sandri; Fosca Bona; Franca Ferrari; Maria Cristina Bonferoni; Carla Caramella
Journal:  AAPS PharmSciTech       Date:  2008-12-03       Impact factor: 3.246

Review 7.  A clinical perspective on mucoadhesive buccal drug delivery systems.

Authors:  Ritu M Gilhotra; Mohd Ikram; Sunny Srivastava; Neeraj Gilhotra
Journal:  J Biomed Res       Date:  2013-06-06

8.  Lidocaine loaded gelatin/gelatinized tapioca starch films for buccal delivery and the irritancy evaluation using chick chorioallantoic membrane.

Authors:  Suchipha Wannaphatchaiyong; Paul Wan Sia Heng; Jirapornchai Suksaeree; Prapaporn Boonme; Wiwat Pichayakorn
Journal:  Saudi Pharm J       Date:  2019-09-25       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.